NASDAQ:SCPS Scopus BioPharma (SCPS) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free SCPS Stock Alerts $0.0011 0.00 (0.00%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$0.0011▼$0.001150-Day Range N/A52-Week Range$0.00▼$0.11Volume950 shsAverage Volume2,990 shsMarket Capitalization$46,288.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsSocial MediaStock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsSocial Media Get Scopus BioPharma alerts: Email Address Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Scopus BioPharma Stock (NASDAQ:SCPS)Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.Read More SCPS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SCPS Stock News HeadlinesApril 17, 2024 | benzinga.comArgent Biopharma Stock (OTC:MGCLF), Quotes and News SummaryFebruary 14, 2024 | uk.investing.comScopus Biopharma Inc (SCPS)April 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.February 7, 2024 | morningstar.comArriVent BioPharma Inc AVBPJanuary 31, 2024 | finance.yahoo.comScopus BioPharma Inc. (SCPS)January 8, 2024 | msn.com7+ Companies That Had Their IPO in 2020: Best and Worst PerformersNovember 7, 2023 | finance.yahoo.comScopus BioPharma’s Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of CancerNovember 2, 2023 | finance.yahoo.comScopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of CancerApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.July 15, 2023 | morningstar.comKinnate Biopharma Inc Ordinary SharesMay 16, 2023 | benzinga.comScopus BioPharma Stock (OTC:SCPS), Insider Trading ActivityApril 19, 2023 | morningstar.comESG Industry Landscape Report: BiopharmaMarch 18, 2023 | benzinga.comYS BIOPHARMA TO RING THE OPENING BELL AND DEBUT ON NASDAQDecember 16, 2022 | benzinga.comShort Volatility Alert: Scopus Biopharma IDecember 15, 2022 | msn.comWhy Planet Labs Shares Are Trading Higher; Here Are 28 Stocks Moving PremarketNovember 10, 2022 | finance.yahoo.comScopus BioPharma’s Subsidiary — Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of CancerOctober 18, 2022 | finance.yahoo.comScopus Biopharma Completes Recapitalization Designed To Enhance Shareholder ValueMay 5, 2022 | finance.yahoo.comScopus BioPharma Announces Biotechnology Industry Leader Rejoins Board of DirectorsMarch 22, 2022 | finance.yahoo.comScopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 3rd Annual STING & TLR-Targeting Therapies SummitJanuary 10, 2022 | finance.yahoo.comScopus BioPharma Provides Update Following Annual Meeting of StockholdersJanuary 6, 2022 | finance.yahoo.comDR. MORRIS C. LASTER WINS PROXY CONTEST AS STOCKHOLDERS ELECT HIS NOMINEES TO SCOPUS BIOPHARMA INC. BOARD OF DIRECTORSDecember 28, 2021 | nasdaq.comScopus Biopharma Inc Shares Approach 52-Week Low - Market MoverDecember 17, 2021 | finance.yahoo.comScopus BioPharma Issues Open Letter to Stockholders Detailing Morris Laster’s Campaign Against the CompanyDecember 7, 2021 | finance.yahoo.comScopus BioPharma Sends Letter Urging Stockholders to Vote “FOR ALL” of the Company’s Director Nominees on the WHITE Proxy CardDecember 6, 2021 | finance.yahoo.comDr. Morris C. Laster Issues An Open Letter To Scopus BioPharma Inc. Stockholders In Connection With Upcoming Annual MeetingNovember 22, 2021 | finance.yahoo.comScopus BioPharma Announces $9.75 Million Private Placement Priced At-The-MarketOctober 8, 2021 | finance.yahoo.comScopus BioPharma Announces Adjournment of Annual Meeting of StockholdersSee More Headlines Receive SCPS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Scopus BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SCPS CUSIPN/A CIK1772028 Webscopusbiopharma.com Phone212-479-2513FaxN/AEmployees13Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.33) per share Price / Book0.00Miscellaneous Outstanding Shares42,080,000Free Float39,938,000Market Cap$46,288.00 OptionableNot Optionable Beta1.01 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Ira Scott Greenspan (Age 65)Senior Advisor & Director Comp: $200kMr. Robert J. GibsonVice Chairman, Secretary & TreasurerDr. Alan D. Horsager Ph.D. (Age 51)President?of?Immuno-Oncology and President & CEO of Duet BioTherapeutics Key CompetitorsStatera BiopharmaNASDAQ:STABNovanNASDAQ:NOVNNVN LiquidationNASDAQ:NOVNQCalithera BiosciencesNASDAQ:CALAIgnyte AcquisitionNASDAQ:IGNYView All Competitors SCPS Stock Analysis - Frequently Asked Questions How have SCPS shares performed in 2024? Scopus BioPharma's stock was trading at $0.0431 on January 1st, 2024. Since then, SCPS stock has decreased by 97.4% and is now trading at $0.0011. View the best growth stocks for 2024 here. How do I buy shares of Scopus BioPharma? Shares of SCPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SCPS) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scopus BioPharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
